Deals11 Feb 2026, 08:23 am
OneSource-Hikma partnership secures approval to commercialise generic Ozempic in Saudi Arabia
AI Summary
OneSource Specialty Pharma Limited has received Saudi Food and Drug Authority (SFDA) approval for its generic Ozempic (semaglutide) in Saudi Arabia. The company will collaborate with Hikma Pharmaceuticals PLC as their exclusive commercialisation partner for the Middle East and North Africa (MENA) region. The partnership aims to capitalise on rising demand for this product and increase access to high-quality affordable generic alternatives to patients across the region.
Key Highlights
- OneSource received SFDA approval for its generic Ozempic (semaglutide) in Saudi Arabia.
- The partnership with Hikma Pharmaceuticals PLC will enable commercialisation in the MENA region.
- The partnership aims to increase access to high-quality and affordable generic alternatives in the region.
- OneSource will manufacture and supply semaglutide from its state-of-the-art facility in Bengaluru.
- Hikma, the largest pharmaceutical company in the MENA region by sales, will use its extensive commercial reach to scale access across both private and institutional channels.